

# Underuse of beta-blockers in patients with heart failure and COPD

**First published:** 26/10/2015

**Last updated:** 01/04/2024

Study

Finalised

## Administrative details

### EU PAS number

EUPAS11387

---

### Study ID

27213

---

### DARWIN EU® study

No

---

### Study countries

 United Kingdom

---

### Study description

Cardiovascular comorbidity is common in chronic obstructive pulmonary disease (COPD). Retrospective cohort studies have shown putative benefits of beta-blockers in COPD. Although beta-blockers are established therapy in heart

failure (HF) guidelines, including for patients with COPD, there remain concerns regarding bronchoconstriction even with cardioselective beta-blockers. We aim to assess the real life use of beta-blockers for patients with HF who also have COPD.

---


## Study status

Finalised

## Research institutions and networks

### Institutions

#### Observational & Pragmatic Research Institute Pte (OPRI)

 United Kingdom

**First published:** 06/10/2015

**Last updated:** 19/08/2024

**Institution**

Educational Institution

Laboratory/Research/Testing facility

ENCePP partner

## Contact details

### Study institution contact

David Price [dprice@opri.sg](mailto:dprice@opri.sg)

Study contact

[dprice@opri.sg](mailto:dprice@opri.sg)

## Primary lead investigator

David Price

Primary lead investigator

## Study timelines

### Date when funding contract was signed

Actual: 15/06/2015

---

### Study start date

Actual: 26/06/2015

---

### Date of final study report

Planned: 20/11/2015

Actual: 23/11/2016

## Sources of funding

- Other

## More details on funding

RiRL

## Regulatory

**Was the study required by a regulatory body?**

No

---

**Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

#### Study type list

**Study topic:**

Disease /health condition

Human medicinal product

---

**Study type:**

Non-interventional study

---

**Scope of the study:**

Drug utilisation

**Data collection methods:**

Secondary use of data

---

**Main study objective:**

To assess the real life use of beta-blockers for patients with HF who also have COPD

## Study Design

## **Non-interventional study design**

Cross-sectional

## Study drug and medical condition

### **Anatomical Therapeutic Chemical (ATC) code**

(C07) BETA BLOCKING AGENTS

BETA BLOCKING AGENTS

(C09) AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

---

### **Medical condition to be studied**

Chronic obstructive pulmonary disease

Cardiac failure

## Population studied

### **Short description of the study population**

Patients with heart failure (HF) who also have chronic obstructive pulmonary disease (COPD).

---

### **Age groups**

- Adults (18 to < 46 years)
  - Adults (46 to < 65 years)
  - Adults (65 to < 75 years)
  - Adults (75 to < 85 years)
  - Adults (85 years and over)
-

## Special population of interest

Other

---

## Special population of interest, other

Chronic obstructive pulmonary disease (COPD) and cardiac failure patients

---

## Estimated number of subjects

125000

## Study design details

### Data analysis plan

Treatments for HF will be compared between groups using multinomial logistic regression, and the odds ratios, 95% confidence intervals, and p-values will be reported.

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

**Data source(s)**

Optimum Patient Care Research Database

---

**Data sources (types)**

[Electronic healthcare records \(EHR\)](#)

## Use of a Common Data Model (CDM)

**CDM mapping**

No

## Data quality specifications

**Check conformance**

Unknown

---

**Check completeness**

Unknown

---

**Check stability**

Unknown

---

**Check logical consistency**

Unknown

## Data characterisation

**Data characterisation conducted**

Unknown